Evaluation of Functional and Cytogenetic High-Risk Multiple Myeloma Using Real-World Data
Treatment Patterns and Outcomes of Patients with Double-Class Refractory or Triple-Class Refractory Multiple Myeloma: A Retrospective US Electronic Health Record Database Study
P-119: Evaluation of real-world frontline treatment for multiple myeloma by race
Real-world next-generation sequencing (NGS) and treatment (Tx) patterns in non-small cell lung cancer (NSCLC) patients (pts) with MET exon 14 skipping mutations (METex14)
Associations Between Amplification (1q) and Prior Cancer in a Real-World De Novo Myeloma Cohort
Real-World Treatment Patterns and Outcomes of Patients with Functional High-Risk (Early Relapse) Multiple Myeloma
74P – Cost of adverse events (AEs) with second-line (2L) immuno-oncology agents (IO) and chemotherapy (CHEMO) in advanced non-small cell lung cancer (aNSCLC) in the real-world
The Unforeseen Medical and Business Challenges Found When Integrating Abstracted Data from Disparate EHR Systems While Building the Curecloud Direct-to-Patient Multiple Myeloma Registry
Chromosome 1q Amplification Is Associated with a History of Prior Malignancies Among Patients Newly Diagnosed with Multiple Myeloma
Rates of genotyping for KRAS, NRAS, BRAF, microsatellite instability (MSI), and mismatch repair (MMR) in metastatic colon cancer patients: Gaps and implications
